101 related articles for article (PubMed ID: 14653064)
1. [Left atrial thrombus in multiple myeloma treated with thalidomide].
Jégo C; Barbou F; Laurent P; Gisserot O; Cellarier G; Bonal J; Bouchiat C; Landais C; de Jaureguiberry JP; Dussarat GV
Arch Mal Coeur Vaiss; 2003 Oct; 96(10):1006-10. PubMed ID: 14653064
[TBL] [Abstract][Full Text] [Related]
2. Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature.
Martin MG; Vij R
Clin Lymphoma Myeloma; 2009 Aug; 9(4):320-3. PubMed ID: 19717384
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma.
Galli M; Elice F; Crippa C; Comotti B; Rodeghiero F; Barbui T
Haematologica; 2004 Sep; 89(9):1141-2. PubMed ID: 15377478
[TBL] [Abstract][Full Text] [Related]
4. [Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan Myeloma Study Group].
Murakami H; Handa H; Imai K; Kanakura Y; Kosaka M; Sawamura M; Shimazaki C; Suzuki K; Ishii A; Takagi T; Taniwaki M; Togawa A; Hata H; Wakayama T; Takatsuki K;
Rinsho Ketsueki; 2004 Jun; 45(6):468-72. PubMed ID: 15287523
[TBL] [Abstract][Full Text] [Related]
5. Should we screen patients for inherited thrombophilia before starting thalidomide?
Otrock ZK; Mahfouz RA; El-Hajj II; Harb MI; Sawaya RA
Am J Clin Oncol; 2006 Feb; 29(1):100-1. PubMed ID: 16462512
[TBL] [Abstract][Full Text] [Related]
6. Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: case report and review of literature.
Prasad HK; Kaushal V; Mehta P
Am J Hematol; 2007 Sep; 82(9):855-7. PubMed ID: 17570510
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
[TBL] [Abstract][Full Text] [Related]
8. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
[TBL] [Abstract][Full Text] [Related]
9. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
Radocha J; Maisnar V
Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
[TBL] [Abstract][Full Text] [Related]
10. [Brief report: stroke in multiple myeloma patient treated with thalidomide].
Ito Y; Mori A; Yonemura K; Hashimoto Y; Hirano T; Uchino M
Rinsho Shinkeigaku; 2007 Sep; 47(9):593-6. PubMed ID: 18018619
[TBL] [Abstract][Full Text] [Related]
11. Arterial thrombosis in four patients treated with thalidomide.
Scarpace SL; Hahn T; Roy H; Brown K; Paplham P; Chanan-Khan A; van Besien K; McCarthy PL
Leuk Lymphoma; 2005 Feb; 46(2):239-42. PubMed ID: 15621807
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide for the treatment of multiple myeloma.
Hattori Y; Iguchi T
Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
[TBL] [Abstract][Full Text] [Related]
13. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Zangari M; Barlogie B; Anaissie E; Saghafifar F; Eddlemon P; Jacobson J; Lee CK; Thertulien R; Talamo G; Thomas T; Van Rhee F; Fassas A; Fink L; Tricot G
Br J Haematol; 2004 Sep; 126(5):715-21. PubMed ID: 15327525
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide and thrombosis.
Mehta P
Clin Adv Hematol Oncol; 2003 Aug; 1(8):464-5. PubMed ID: 16258433
[No Abstract] [Full Text] [Related]
15. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
[TBL] [Abstract][Full Text] [Related]
16. Arterial thrombosis and thalidomide.
Goz M; Eren MN; Cakir O
J Thromb Thrombolysis; 2008 Apr; 25(2):224-6. PubMed ID: 17514361
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates.
Gieseler F
Thromb Haemost; 2008 Jun; 99(6):1001-7. PubMed ID: 18521500
[TBL] [Abstract][Full Text] [Related]
18. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
Mileshkin L; Stark R; Day B; Seymour JF; Zeldis JB; Prince HM
J Clin Oncol; 2006 Sep; 24(27):4507-14. PubMed ID: 16940275
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide therapy and polyneuropathy in myeloma patients.
Laaksonen S; Remes K; Koskela K; Voipio-Pulkki LM; Falck B
Electromyogr Clin Neurophysiol; 2005 Mar; 45(2):75-86. PubMed ID: 15861857
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Poser M; Müller S; Flasshove M; Moritz T; Seeber S; Nowrousian MR
Ann Hematol; 2005 Sep; 84(9):594-600. PubMed ID: 15744524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
